A Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Brief description of study
The purpose of this study is to compare the effects and safety of tislelizumab plus chemotherapy to placebo (an inactive substance) plus chemotherapy on you and your Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJ) to find out the most effective treatment. In this study, you will receive either tislelizumab plus chemotherapy or placebo plus chemotherapy. Tislelizumab is an investigational drug, which means that the study drug is currently being tested and health authorities such as the Food and Drug Administration (FDA) in the United States have not approved tislelizumab for the treatment of Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJ).
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
